Measuring blood clotting and inflammation in people with advanced liver cirrhosis
Tests new blood assays for clotting and inflammation in adults with decompensated liver cirrhosis.
Plain-language title generated from the registry record
Registry title: Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Key facts
- Where
- Stockholm, SwedenSee the site
Where in Sweden
- Karolinska University HospitalStockholm, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Stockholm
- Trial code
- NCT06212635
- Record updated
- 19 January 2024
- Original description
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.Read full original descriptionShow less
Novel Biomarkers for Evaluation of Hemostasis and Inflammation in Liver Cirrhosis
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Inclusion: Patients with decompensated liver cirrhosis; 18 years or older; Healthy individuals 18 years or older will serve as controls.
Exclusion: • Extrahepatic malignancy or recurrence of such within the last year; Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion; Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies; Previous liver transplantation; Transfusions the last 7 days; Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken >12 hours after the last injection.